Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

BioNTech SE (BNTX)

NASDAQ
Symbol
Exchange
Currency
BNTXNASDAQUSD
BNTXNBIVAMXN
22UAyXetraEUR
22UAyFrankfurtEUR
22UAyTradeGateEUR
BNTXViennaEUR
Currency in USD
Disclaimer
86.17
-0.23(-0.27%)
Closed
After Hours
86.99+0.82(+0.95%)

BNTX Comments

Any news from anti-cancer works?..
hope BNTX will bring their anti-cancer pipeline of the future forward so this will go to moon again and beyond! I especially love the fact that they are developing something against lung cancer!
300% Gain from here Gauranteed
Thank you MM
Strong Buy. This is a steal!
How about those earnings?! 👀
sold this trash... bye bye
who want buy this can you tell me. So many court is coming. They will must pay a lot for deaths. Full twitter so whole world know
Will buy more..
They cant be sued. They had all emergency approval, meaning all goverments waived the right to sue. That was a free lunch for these companies...you have to sue the governments
The mRNA vaccine looks like a joke in the vaccine history. It couldn't stop COVID infection and spreading. Biden, Fauci, the head of CDC and The CEO of Pfizer were infected COVID virus after they got 4 shots of mRNA vaccine. Does mRNA vaccine can generate enough folded spike protein as antigen for Antigen presenting cells? Who knows? mRNA vaccine looks like generating shot term nonspecific immune response by its longer RNA chain.
You mean China is a big performer. Funny.
Anyone can recommend me some books to improve my operations? In particular on how to manage my capital. Thank you
It looks like the world is about to dive further into turmoil with a new wave of covid coupled with recession and panic
I think the vaccine stocks could be the only way to go
No direction yet
🚀🔆Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose.
Covid is done, just like this stock. No movea will occur Until they produce something from their pipeline
Coming soon I believe..
🚀 Great entry point for Therapeutics ready to release from the huge pipeline!
covid globe it is best isn't it?
🚀 BioNTech submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as children ages 5 through <12).The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose approximately 6 months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10-µg two-dose primary series, which was authorized under EUA for this age group in October 2021. Data from this study demonstrated a strong immune response in this age group following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine with no new safety signals.
BNTX will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022.
New variants will keep BNTX consistently developing, keeping the public guarded, and deriving steady revenue upsurges...
rrrrright.....
Bellow 100$ in summer
sure sure... take that pill and RIP!
now, it seems that you made an excellent guess
Rob Roo, you told everyone to buy when it was 350. Pathetic.
You're a big boy, you can make your own decisions...
Buy this temporary dip!!!
BNTX announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. These data demonstrate an increase in SARS-CoV-2 Omicron variant and wild-type strain neutralizing titers following a booster dose of the Pfizer-BioNTech COVID-19 vaccine compared to two doses. These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group.
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.